ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 77 filers reported holding ORIC PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $805,291 | -28.7% | 133,106 | -8.6% | 0.00% | – |
| Q2 2023 | $1,129,476 | +58.2% | 145,551 | +16.2% | 0.00% | – |
| Q1 2023 | $713,851 | +269.7% | 125,237 | +282.1% | 0.00% | – |
| Q4 2022 | $193,074 | +103.2% | 32,780 | +11.1% | 0.00% | – |
| Q3 2022 | $95,000 | -14.4% | 29,518 | +18.8% | 0.00% | – |
| Q2 2022 | $111,000 | -31.5% | 24,857 | -18.1% | 0.00% | – |
| Q1 2022 | $162,000 | -85.9% | 30,341 | -61.0% | 0.00% | – |
| Q4 2021 | $1,145,000 | +322.5% | 77,863 | +500.1% | 0.00% | – |
| Q3 2021 | $271,000 | -22.8% | 12,974 | -34.5% | 0.00% | – |
| Q2 2021 | $351,000 | +39.3% | 19,814 | +92.4% | 0.00% | – |
| Q1 2021 | $252,000 | +183.1% | 10,299 | +288.2% | 0.00% | – |
| Q4 2020 | $89,000 | +117.1% | 2,653 | +60.7% | 0.00% | – |
| Q3 2020 | $41,000 | -90.9% | 1,651 | -87.6% | 0.00% | – |
| Q2 2020 | $451,000 | – | 13,360 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 4,768,181 | $161,403,000 | 14.64% |
| Invus Financial Advisors, LLC | 1,007,575 | $34,106,000 | 14.26% |
| Euclidean Capital LLC | 1,400,435 | $47,405,000 | 10.04% |
| Memorial Sloan Kettering Cancer Center | 602,272 | $20,387,000 | 8.63% |
| EcoR1 Capital, LLC | 3,092,218 | $104,672,000 | 5.63% |
| Ally Bridge Group (NY) LLC | 413,061 | $13,982,000 | 2.40% |
| Asymmetry Capital Management, L.P. | 67,210 | $2,275,000 | 1.04% |
| Orbimed Advisors | 2,921,967 | $98,909,000 | 0.86% |
| Casdin Capital, LLC | 601,515 | $20,361,000 | 0.60% |
| EMERALD ADVISERS, LLC | 522,302 | $17,680,000 | 0.59% |